STAIR Narrative Therapy Restores Cognitive Function in Complex PTSD: First Evidence from Japan

Complex PTSD damages cognition. This is not disputed. Meta-analyses have documented deficits in memory, attention, and executive function across PTSD populations, and the disturbances of self-organization that define cPTSD — affective dysregulation, negative self-concept, interpersonal disturbance — suggest even deeper neurocognitive compromise. What has been disputed is whether treatment can reverse these deficits, or whether they represent permanent neural scarring from prolonged childhood adversity. Niwa and colleagues in Japan designed the first study to directly test this question for cPTSD.

The protocol

STAIR Narrative Therapy is a two-phase treatment developed by Marylene Cloitre specifically for complex trauma. Phase 1 (STAIR — Skills Training in Affective and Interpersonal Regulation) builds emotional and relational capacities. Phase 2 (Narrative Therapy) processes traumatic memories through structured narrative construction. The model follows the phase-based consensus for complex trauma treatment: stabilize first, process second. What makes this study unusual is not the therapy. It is the outcome measure.

Niwa's team assessed neurocognitive functioning using the RBANS — a validated neuropsychological battery that measures five domains: immediate memory, visuospatial/constructional ability, language, attention, and delayed memory — plus a global score. Thirteen women with ICD-11 cPTSD related to childhood abuse completed assessments at three time points: before treatment, immediately after, and three months post-treatment.

The findings

The results are selective and that selectivity is informative. Immediate memory and global cognitive functioning improved significantly at the 3-month follow-up compared to pretreatment. The other domains — visuospatial construction, attention, language, delayed memory — did not change significantly.

This pattern makes theoretical sense. Immediate memory involves encoding and short-term retention — processes heavily dependent on prefrontal-hippocampal circuits that are disrupted by chronic stress and hyperarousal. STAIR's Phase 1 specifically trains affective regulation, which reduces chronic autonomic arousal. Lower arousal means better prefrontal function. Better prefrontal function means better encoding. The improvement in global cognitive scores likely reflects the downstream effect of restored immediate memory capacity on overall test performance.

The domains that did not improve — visuospatial construction, language — are less directly impacted by trauma-related arousal dysregulation. Their stability is not a failure. It is specificity. The therapy appears to restore cognitive functions that were impaired by the mechanism it targets (affective dysregulation), while leaving intact those that were never the primary casualty.

The timing question

The improvement appeared at three months, not immediately post-treatment. This delayed effect is clinically important. It suggests that STAIR's cognitive benefits emerge through a consolidation process — the skills learned in therapy gradually reshape neural functioning over weeks and months, rather than producing instant cognitive enhancement. This is consistent with neuroplasticity timelines documented in other treatment modalities (exercise, meditation, cognitive rehabilitation).

What this means at the bedside

N=13, no control group, single-arm pilot. These are serious limitations that demand replication before clinical conclusions. But the finding fills a gap that has troubled trauma clinicians for years. Patients with complex PTSD often report cognitive fog, forgetfulness, difficulty concentrating — and clinicians have largely responded with validation rather than intervention, because the assumption was that these deficits were structural consequences of developmental trauma.

This study suggests otherwise. If replicated, it means that cPTSD-specific treatment does not just reduce symptom scales — it may restore cognitive capacities that patients need for daily functioning, occupational performance, and further therapeutic work. For clinicians treating complex trauma: assess neurocognitive functioning at intake. Not as a research exercise, but as a baseline that may demonstrate improvement over the course of treatment. It gives patients — and you — evidence that the work is changing their brain, not just their questionnaire scores.